Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mayocp.2021.03.015 http://scihub22266oqcxt.onion/10.1016/j.mayocp.2021.03.015 33958053!7997730!33958053     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mayo+Clin+Proc 2021 ; 96 (5): 1165-1174 Nephropedia Template TP {{tp|p=33958053|t=2021. Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center |pdf=|usr=}}{{33958053}} gab.com Text Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center JO: Mayo Clin Proc http://www.kidney.de/pget.php?&tw=1&pmid=33958053 #FOAvip OBJECTIVE: To estimate the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in health care personnel. METHODS: The Mayo Clinic Serology Screening Program was created to provide a voluntary, two-stage testing program for SARS-CoV-2 antibodies to health care personnel. The first stage used a dried blood spot screening test initiated on June 15, 2020. Those participants identified as reactive were advised to have confirmatory testing via a venipuncture. Venipuncture results through August 8, 2020, were considered. Consent and authorization for testing was required to participate in the screening program. This report, which was conducted under an institutional review board-approved protocol, only includes employees who have further authorized their records for use in research. RESULTS: A total of 81,113 health care personnel were eligible for the program, and of these 29,606 participated in the screening program. A total of 4284 (14.5%) of the dried blood spot test results were "reactive" and warranted confirmatory testing. Confirmatory testing was completed on 4094 (95.6%) of the screen reactive with an overall seroprevalence rate of 0.60% (95% CI, 0.52% to 0.69%). Significant variation in seroprevalence was observed by region of the country and age group. CONCLUSION: The seroprevalence for SARS-CoV-2 antibodies through August 8, 2020, was found to be lower than previously reported in other health care organizations. There was an observation that seroprevalence may be associated with community disease burden. Twit Text FOAVip Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center ????Mayo Clin Proc http://www.kidney.de/pget.php?&tw=1&pmid=33958053 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33958053 #FOAvip English Wikipedia <ref>{{Cite pmid|33958053}}</ref> Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center #MMPMID33958053 Carter RE; Theel ES; Breeher LE; Swift MD; Van Brunt NA; Smith WR; Blanchfield LL; Daugherty EA; Chapital AB; Matson KM; Bews KA; Johnson PW; Domnick RA; Joyce DE; Geyer HL; Granger D; Hilgart HR; Turgeon CT; Sanders KA; Matern D; Nassar A; Sampathkumar P; Hainy CM; Orford RR; Vachon CM; Didehban R; Morice WG; Ting HH; Williams AW; Gray RJ; Thielen KR; Farrugia G Mayo Clin Proc 2021[May]; 96 (5): 1165-1174 PMID33958053show ga OBJECTIVE: To estimate the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in health care personnel. METHODS: The Mayo Clinic Serology Screening Program was created to provide a voluntary, two-stage testing program for SARS-CoV-2 antibodies to health care personnel. The first stage used a dried blood spot screening test initiated on June 15, 2020. Those participants identified as reactive were advised to have confirmatory testing via a venipuncture. Venipuncture results through August 8, 2020, were considered. Consent and authorization for testing was required to participate in the screening program. This report, which was conducted under an institutional review board-approved protocol, only includes employees who have further authorized their records for use in research. RESULTS: A total of 81,113 health care personnel were eligible for the program, and of these 29,606 participated in the screening program. A total of 4284 (14.5%) of the dried blood spot test results were "reactive" and warranted confirmatory testing. Confirmatory testing was completed on 4094 (95.6%) of the screen reactive with an overall seroprevalence rate of 0.60% (95% CI, 0.52% to 0.69%). Significant variation in seroprevalence was observed by region of the country and age group. CONCLUSION: The seroprevalence for SARS-CoV-2 antibodies through August 8, 2020, was found to be lower than previously reported in other health care organizations. There was an observation that seroprevalence may be associated with community disease burden. |*COVID-19 Serological Testing/methods/statistics & numerical data[MESH] |*COVID-19/blood/epidemiology/therapy[MESH] |*SARS-CoV-2/immunology/isolation & purification[MESH] |Academic Medical Centers[MESH] |Adult[MESH] |Antibodies, Viral/*blood[MESH] |Disease Transmission, Infectious/*statistics & numerical data[MESH] |Female[MESH] |Health Personnel/*statistics & numerical data[MESH] |Humans[MESH] |Immunoglobulin G/blood[MESH] |Male[MESH] |Middle Aged[MESH] |Public Health/methods[MESH] |Seroepidemiologic Studies[MESH] |Spatio-Temporal Analysis[MESH]Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical C(epmc).pdf DeepDyve Pubget Overpricing